中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

手术切除与射频消融治疗符合米兰标准的不同肝段多发肝癌的效果分析

王宁 郑金利 蒋利

引用本文:
Citation:

手术切除与射频消融治疗符合米兰标准的不同肝段多发肝癌的效果分析

DOI: 10.3969/j.issn.1001-5256.2020.04.017
基金项目: 

四川省重点课题(00402053A2117); 

详细信息
  • 中图分类号: R735.7

Clinical effect of surgical resection versus radiofrequency ablation in treatment of multiple liver cancer in different liver segments meeting the Milan criteria

Research funding: 

 

  • 摘要: 目的探讨手术切除与射频消融治疗多发位于不同肝段符合米兰标准肝癌的效果。方法回顾性分析2009年2月-2013年2月在华西医院肝脏外科及肝移植中心行手术切除及射频消融术的多发位于不同肝段的符合米兰标准的158例肝癌患者的临床资料,手术切除110例,射频消融48例。比较两种治疗方法的效果差异。计数资料2组间比较采用χ2检验或Fisher确切检验;计量资料满足正态分布的2组间比较采用t检验,不满足正态分布的2组间比较采用Mann-Whitney U检验;采用KaplanMeier分析总体生存率及无瘤生存率,生存率比较采用log-rank检验。采用受试者工作特征曲线(ROC曲线)分析肿瘤分化程度与微脉管侵犯的关系。结果射频消融组患者血红蛋白、Alb较手术切除组低(P值均<0. 05),术后住院时间较手术切除组短(P <0. 05)。手术切除组与射频消融组患者预后差异无统计学意义(1、3、5年总体生存率分别为94. 5%、55. 2%、28. 8%和83. 3%、50. 0%、26. 5%,χ2=1. 161,P=0. 281; 1、3、5...

     

  • [1] ZHAO C,NGUYEN MH. Hepatocellular carcinoma screening and surveillance:Practice guidelines and real-life practice[J]. Clin Gastroenterol,2016,50(2):120-33.
    [2] MAZZAFERRO V,REGALIA E,DOCI R,et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med,1996,334(11):693-699.
    [3] HASEGAWA K,KOKUDO N,MAKUUCHI M,et al. Comparison of resection and ablation for hepatocellular carcinoma:A cohort study based on a Japanese nationwide survey[J]. J Hepatol,2013,58(4):724-729.
    [4] LIM KC,CHOW PK,ALLEN JC,et al. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria[J]. Br J Surg,2012,99(12):1622-1629.
    [5] MINAMI Y,KUDO M. Radiofrequency ablation of hepatocellular carcinoma:A literature review[J]. Int J Hepatol,2011,2011:104685.
    [6] LAM VW,NG KK,CHOK KS,et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma[J]. J Am Coll Surg,2008,207(1):20-29.
    [7] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepotol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
    [8] CLAVIEN PA,BARKUN J,de OLIVEIRA ML,et al. The Clavien-Dindo classification of surgical complications:Fiveyear experience[J]. Ann Surg,2009,250(2):187-196.
    [9] PANG YY. The Brisbane 2000 terminology of liver anatomy and resections[J]. HPB(Oxford),2002,4(2):99.
    [10] MA KW,SHE WH,CHEUNG TT,et al. Validated nomogram for the prediction of disease-free survival after hepatectomy for hepatocellular carcinoma within the Milan criteria:Individualizing a surveillance strategy[J]. Surg Today,2019,49(6):521-528.
    [11] IMURA S,TERAOKU H,YOSHIKAWA M,et al. Potential predictive factors for microvascular invasion in hepatocellular carcinoma classifed within the Milan criteria[J]. Int J Clin Oncol,2018,23(1):98-103.
    [12] GAO J,WANG SH,DING XM,et al. Radiofrequency ablation for single hepatocellular carcinoma 3 cm or less as first-line treatment[J]. World J Gastroenterol,2015,21(17):5287-94.
    [13] GOUW AS,BALABAUD C,KUSANO H,et al. Markers for microvascular invasion in hepatocellular carcinoma:Where do we stand?[J]. Liver Transpl,2011,17(Suppl 2):s72-s80.
    [14] ZHANG X,LI J,SHEN F,LAU WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol,2018,33(2):347-354.
    [15] RODRIGUEZ-PERALVAREZ M,LUONG TV,ANDREANA L,et al. A systematic review of microvascular invasion in hepatocellular carcinoma:Diagnostic and prognostic variability[J].Ann Surg Oncol,2012,20(1):325-39.
    [16] TAKAMORI R,WONG LL,DANG C,et al. Needle-tract implantation from hepatocellular cancer:Is needle biopsy of the liver always necessary?[J]. Liver Transpl,2000,6(1):67-72.
    [17] ADACHI E,MAEHARA S,TSUJITA E,et al. Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma[J]. Surgery,2002,131(1):s148-s152.
  • 加载中
计量
  • 文章访问数:  1290
  • HTML全文浏览量:  91
  • PDF下载量:  200
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-10-29
  • 出版日期:  2020-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回